

ATCIP 2025

Antimicrobial Therapy in
Immunocompromised
and Critically Ill Patients:
Management and
Perspectives

8-9 May 2025

Villa Sassa Hotel, Via Tesserete 10, Lugano

www.atcip.org



ATCIP2025

UPDATE ON THE THERAPY OF IMMUNOCOMPROMISED AND CRITICALLY ILL PATIENTS

Critically ill patients are at increased risk of developing severe and often fatal infections and infectious complications. A large investment of financial and medical resources has improved outcomes, but the optimal treatment options for these patients are still matter of discussions among the experts.

Infections, sepsis, and septic shock are leading causes of morbidity and mortality in the intensive care unit (ICU), and physicians dedicate many resources to their prevention, diagnosis, and therapy, as well as to the evaluation of the treatment outcomes. Improvement in the management of infections in critically ill patients at high risk for complications, and decrease of adverse outcomes, will most likely be the results of better quality of care, the development of new models to evaluate outcomes data, questioning and revising currently accepted standards of care, the implementation of new ideas and the performance of innovative clinical trials, and a paradigm shift in the treatment procedures, considering that the slow pace observed in the development of new, effective antibiotics cannot be the driving force of progress. The fast advances in the development of mathematical models evaluating infectious processes, including genetics as well as statistical and artificial intelligence modelling, are also key to a reliable evaluation of causes and therapeutic approaches, ultimately improving outcomes of infectious disease.

With a focus on practical aspects, the seventh congress on Antimicrobial Therapy in Immunocompromised and Critically Ill Patients (ATCIP) will review the latest advances in the epidemiology, diagnosis, and therapy of infections in immunocompromised and critically ill patients. Experts will provide an updated insight in the research and therapy of infectious diseases during plenary sessions and an interactive session. Advances in clinical mycology, as well as the progress in the epidemiology, diagnosis, and therapy of infectious concomitant diseases in solid organ transplanted (SOT) patients will be discussed. A session will be dedicated to the use of new vaccines in immunocompromised patients and the infectious complications of cellular treatments in oncology. Experts will also discuss the use of new antivirals and other therapies in Hepatitis B and D as well as the use of ART in HIV. Infectious disease in the ICU will also have a prominent role, with talks reviewing the importance of sinks, the opportunities and obstacles associated with the use of AI, and the implementation of the new FUNGINOS aspergillosis guidelines in the ICU. The programme will be completed with satellite symposia discussing recent advances in the development of new drugs and treatment options. Overall, the congress promises to become not only an exciting opportunity to learn from internationally known experts, but also to be an important networking platform that will allow clinical practitioners to interact with leading researchers in the infectious diseases field.

WELCOME TO LUGANO

Lugano is a charming small town located in Southern Switzerland. It can be easily and rapidly reached by train or bus from the Malpensa airport. The congress venue is the Villa Sassa Hotel, conveniently located at walking distance from the Lugano Main Station and downtown. The town has excellent facilities, and the superb surroundings make it an appreciated tourist attraction. Participants will be able to attend a highly educational meeting while enjoying the tourist attractions and the gastronomy of the region.

OBJECTIVES

At the end of the congress, the participants should be able to approach the most common issues and controversies related to difficult-to-treat infectious diseases in immunocompromised and critically ill patients and have gathered not only theoretical but also real-life experience to be translated into daily clinical practice.

WHO SHOULD ATTEND

Infectious disease and intensive care specialists, oncologists and haemato-oncologists, transplant specialists, clinical microbiologists, as well as other health professionals involved in the care of critically ill and immunocompromised patients.

SCIENTIFIC COMMITTEE

ENOS BERNASCONI, MD, Lugano, Switzerland
LUIGIA ELZI, MD, Locarno, Switzerland
CHRISTIAN GARZONI, MD, Lugano, Switzerland
PAOLO GROSSI, MD, Varese, Italy
OSCAR MARCHETTI, MD, Morges and Lausanne, Switzerland
MATTEO MOMBELLI, MD, Locarno, Switzerland
LINDA MÜLLER, PhD, Bellinzona, Switzerland
ORLANDO PETRINI, PhD, Lugano, Switzerland

WED 7 MAY 2025
(afternoon)

ADMINISTRATIVE SESSIONS
closed meetings for members only

16.00-18.00 **General Assemblies**
STCS Infectious Diseases
Funginos

THU 8 MAY 2025

09.20 WELCOME, INTRODUCTION

FUNGINOS SYMPOSIUM: FUNGAL INFECTIONS

Chairs: TBD

09.30 Introduction

09.40 Candida auris

FRÉDÉRIC LAMOTH, Lausanne, Switzerland

10.00 Invasive aspergillosis in lung transplant patient

LAURA WÄLTI, Bern, Switzerland

10.20 Molecular diagnostics

LAURENCE MILLON, Besançon, France

10.40 Urinary tract infections by non-albicans

Candida species

NINA KHANNA, Basel, Switzerland

11.00 Q&A - Discussion

 11.20 **Sponsored Symposium 1**12.20  LUNCH**STCS SYMPOSIUM**

Chairs: TBD

13.10 CAR-T cells to treat infectious diseases

PATRIZIA COMOLI, Pavia, Italy

13.30 CMV prevention in SOT patients

CÉDRIC HIRZEL, Basel, Switzerland

13.50 SOT in HBV, HCV, HDV, and HEV

infected patients

PATRIZIA BURRA, Padua, Italy

14.10 Metagenomics of infectious diseases

CLAIRE BERTELLI, Lausanne, Switzerland

14.30 Q&A - Discussion

SESSION III: ONCOLOGY

Chair: BERNARD GERBER, Bellinzona, Switzerland

14.45 Vaccines' choice for the immunocompromised

traveller. Challenges in the approach to the

immunocompromised traveller

GILLES ÉPERON, Geneva, Switzerland

15:05 Infectious complications of cellular treatments

in oncology

ERIKA KAMPOURI, Lausanne, Switzerland

15.25 Neutropenic enterocolitis: fresh blood

on an old concept

PIERRE-YVES BOCHUD, Lausanne, Switzerland

15.45 Q&A - Discussion

15.55  COFFEE BREAK 16.15 **Sponsored Symposium 2****SESSION IV: NEW ANTIVIRALS AND THERAPIES FOR HBV, HDV, AND HIV**

Chairs: TBD

17.15 HBV/HDV

PIETRO LAMPERTICO, Milan, Italy

17.35 Modern ART

*ALEXANDRA CALMY, Geneva, Switzerland*18.15 **CONCLUDING REMARKS**

FRI 9 MAY 2025

SESSION V: ICU

Chairs: PAOLO MERLANI, Lugano, Switzerland

08.30 Are sinks in the ICU a thing of the past?

GAUD CATHO, Geneva & Sion, Switzerland

08.50 Situation Awareness in the ICU:

Visual Patient Avatar

*DAVID TSCHOLL, Zurich, Switzerland*09.10 New guidelines on invasive aspergillosis in the ICU
Epidemiology*WERNER ALBRICH, St Gallen, Switzerland*

Definitions

DYONISIOS NEOFYTOS, Geneva, Switzerland

Diagnosis

FRÉDÉRIC LAMOTH, Lausanne, Switzerland

Management

NINA KHANNA, Basel, Switzerland

09.55 Q&A - Discussion

10.10  COFFEE BREAK 10.30 **Sponsored Symposium 3** 11.05 **Sponsored Symposium 4**11.50  LUNCH 13.00 **Sponsored Lecture 5****SESSION VI: INTERACTIVE CASES**16.30 **CLOSING REMARKS**

DAY 1 | 8 MAY 2025 | 11.20-12.20

1 ViiV SPONSORED SYMPOSIUM



DAY 1 | 8 MAY 2025 | 16.25-17.15

2 Pfizer SPONSORED SYMPOSIUM



- 16.25 Introduction
- 16.30 RSV Vaccines
ULRICH HEININGER, Basel, Switzerland
- 16.45 Infections by carbapenem-resistant
Enterobacteriaceae
DIEGO ANDREY, Geneva, Switzerland

DAY 2 | 9 MAY 2025 | 10.30-11.00

3 MSD SPONSORED SYMPOSIUM



DAY 2 | 9 MAY 2025 | 11.05-11.50

4 Gilead SPONSORED SYMPOSIUM



Optimizing antifungal treatment
DIONYSIOS NEOFYTOS, Geneva, Switzerland

DAY 2 | 9 MAY 2025 | 13.00-13.45

5 LATE BREAKING TOPICS IN
INFECTIOUS DISEASE

REGISTRATION FEES

FULL CONGRESS	Before APRIL 7TH	After APRIL 7TH	Last minute On-site
Physicians, PhD, other academics	250.00 CHF	330.00 CHF	350.00 CHF
Nurses	150.00 CHF	160.00 CHF	180.00 CHF
Resident Physicians, Postdoctoral students*	100.00 CHF	110.00 CHF	130.00 CHF
Students	50.00 CHF	75.00 CHF	75.00 CHF

Fees include VAT (8.1%)

* Residents (holding an M.D. degree and practicing medicine in a hospital or clinic under the direct or indirect supervision of an attending physician) and postdoctoral students should produce a certification by their supervisors at the time of getting their congress material on site.

REGISTRATION FEE INCLUDES:

- Participation in the conference
- Access to the Exhibition Area
- Conference kit
- Lunches
- Coffee breaks
- Certificate of attendance

VENUE

Villa Sassa Hotel

Via Tesserete 10
6900 Lugano
Switzerland



WITH THE UNCONDITIONAL SUPPORT OF:



ORGANIZING SECRETARY



Via Coremmo , 1 - 6900 Lugano, Switzerland
Tel. +41 (0)91 9676803 - +39 02 86882050
info@atcip.org - www.atcip.org